Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
MRNS.US
id: 1245

Marinus Pharmaceuticals (MRNS) Failed Clinical Trial Case

E.D. Pennsylvania
Court
2:24-cv-02430
Case number
03/17/2021
Class period Start
05/07/2024
Class period End
08/05/2024
Lead Plaintiff motion deadline
  • $MRNS stockholder filed a claim against Marinus Pharmaceuticals for hiding the risks and potential failure of the RAISE clinical trial.
  • On April 15, 2024, on announcement of RAISE trial setback, $MRNS plummeted 82%, losing $341M+ in shareholder value.
  • Marinus investors can join this case to be notified about potential recovery.
Case Details:

On April 15, 2024, Marinus Pharmaceuticals issued a press release revealing that the RAISE trial had not met early stopping criteria and also that the Company would implement cost-saving measures.

On this news, $MRNS plummeted 82% losing $341M+ in shareholder value, and continued its decline on April 16, falling 7% and losing another $5.4M+.

On May 8, 2024, Marinus announced halting RAISE and RAISE II trials, a 20% workforce reduction, and other efficiency measures.

Moreover, Fierce Biotech reported Marinus laying off 20% of staff due to Phase 3 RAISE trial struggles.

On this news, $MRNS fell 8.91% that same day.

Based on these events, $MRNS stockholder filed a claim against Marinus and its leaders, accusing them of the following:
  • Marinus downplayed the risk of failing early-stopping criteria in the RAISE trial.
  • They also didn't disclose that failing could stop the Phase 3 RAISE II trial.
Considering all the representations, investors suspect Marinus hid the risks and potential failure of the RAISE clinical trial.
Case Status
Lead Plaintiff Appointed
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
04/15/2024
Filing date
06/05/2024
Lead Plaintiff Deadline
08/05/2024
Collecting participants…

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure d...

    Ticker
    MRNS.US
    ISIN
    US56854Q1013
    CIK
    1267813
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    5 Radnor Corporate Center, Radnor, PA, United States, 19087